Ampio Pharm
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.
Market Cap & Net Worth: Ampio Pharm (AMPE)
Ampio Pharm (PINK:AMPE) has a market capitalization of $681.21 ($681.21) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #48588 globally and #14916 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ampio Pharm's stock price $0.00 by its total outstanding shares 1135358 (1.14 Million).
Ampio Pharm Market Cap History: 2015 to 2025
Ampio Pharm's market capitalization history from 2015 to 2025. Data shows change from $940.02 Million to $681.21 (-77.37% CAGR).
Ampio Pharm Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ampio Pharm's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
808.96x
Ampio Pharm's market cap is 808.96 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $940.02 Million | $1.16 Million | -$32.01 Million | 808.96x | N/A |
Competitor Companies of AMPE by Market Capitalization
Companies near Ampio Pharm in the global market cap rankings as of March 18, 2026.
Key companies related to Ampio Pharm by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Ampio Pharm Historical Marketcap From 2015 to 2025
Between 2015 and today, Ampio Pharm's market cap moved from $940.02 Million to $ 681.21, with a yearly change of -77.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $681.21 | -76.92% |
| 2024 | $2.95K | -99.87% |
| 2023 | $2.33 Million | -54.48% |
| 2022 | $5.11 Million | -97.37% |
| 2021 | $194.15 Million | -64.15% |
| 2020 | $541.57 Million | +172.73% |
| 2019 | $198.57 Million | +47.67% |
| 2018 | $134.47 Million | -90.30% |
| 2017 | $1.39 Billion | +352.12% |
| 2016 | $306.62 Million | -67.38% |
| 2015 | $940.02 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Ampio Pharm was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $681.21 USD |
| MoneyControl | $681.21 USD |
| MarketWatch | $681.21 USD |
| marketcap.company | $681.21 USD |
| Reuters | $681.21 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.